Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445234 | 0.86 | PTGES (0.48) | PTGESALOX5LTB4R2NPC1RAB9A | |
| SCHEMBL443664 | 0.83 | CA2 (0.35) | PTGESALOX5LTB4R2NPC1RAB9A | |
| SCHEMBL446828 | 0.82 | LTB4R2 (0.43) | PTGESALOX5LTB4R2NPC1RAB9A | |
| SCHEMBL444303 | 0.80 | CFTR (0.49) | PTGESALOX5LTB4R2NPC1RAB9A | |
| SCHEMBL446224 | 0.80 | GAA (0.53) | HDAC6LTB4R2NPC1RAB9AKMT2A | |
| SCHEMBL443857 | 0.78 | KDM4E (0.41) | LTB4R2KMT2A | |
| SCHEMBL446107 | 0.77 | LTB4R2 (0.44) | HDAC1HDAC6HDAC8HDAC5PTGES | |
| SCHEMBL444612 | 0.76 | CA2 (0.46) | PTGESALOX5LTB4R2KMT2A | |
| SCHEMBL446471 | 0.75 | LTB4R2 (0.58) | LTB4R2 | |
| SCHEMBL446132 | 0.74 | LTB4R2 (0.45) | LTB4R2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | HDAC1 2495/4885HDAC6 3644/4885HDAC8 3454/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | HDAC1 2495/4885HDAC6 3644/4885HDAC8 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.